Screening for dihydropyrimidine dehydrogenase deficiency: To do or not to do, that's the question

Cancer Investigation

Volumn 24, Issue 2, 2006, Pages 215-217

  Van Kuilenburg, André B P ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Dihydropyrimidine dehydrogenase; DPYD; Pharmacogenetics; Toxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG METABOLISM; ENZYME DEFICIENCY; GENE ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEAD AND NECK CANCER; HUMAN; INFORMATION DISSEMINATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SCREENING TEST; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; MASS SCREENING; NEOPLASMS;

EID: 33645013092     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500524702     Document Type: Short Survey

References (15)

1. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A.K.; et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ 2004, 329, 15-19.
2. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Eng. J. Med. 2005, 325 (5), 476-487.
3. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 1998, 16, 3537-3541.
4. van Kuilenburg, A.B.P.; Haasjes, J.; Richel, D.J.; Zoetekouw, L.; van Lenthe, H.; et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 2000, 6, 4705-4712.
5. Milano, G.A.; Etienne, M.C.; Pierrefite, V.; Barberi-Heyob, M.; Deporte-Fety, R.; Renée, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 1999, 79, 627-630.
6. Johnson, M.R.; Diasio, R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 2001, 41, 151-157.
7. van Kuilenburg, A.B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 2004, 40, 939-950.
8. 13C-uracil breath test. Clin. Cancer Res. 2004, 10, 2652-2658.
9. van Kuilenburg, A.B.P.; Meinsma, J.R.; Zoetekouw, L; van Gennip, A.M. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+Ig>a mutation. Int. J. Cancer 2002, 101, 253-258.
10. van Kuilenburg, A.B.P.; Van Lenthe, H.; Tromp, A.; Veltman, P.C.J.; van Gennip, A.H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 2000, 46, 9-17.
11. Gardiner, S.J.; Begg, EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet. Genomics 2005, 15 (5), 365-369.
12. Volk, J.; Reinke, F.; van Kuilenburg, A.B.P.; van Gennip, A.H.; Schlichting, C.; Ganser, A.; Schöffski, P. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann. Oncol. 2001, 72, 569-571.
13. Douillard, J.-Y.; Hoff, P.M.; Skillings, J.R.; Eisenberg, P.; Davidson, N.; et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002, 20, 3605-3616.
14. Carmichael, J.; Popiela, T.; Radstone, D.; Falk, S.; Borner, M.; et al. Randomized comparitive study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002, 20, 3617-3627.
15. Electronic file. Available at: http://www.emea.eu.int/humandocs/Humans/ EPAR/Xeloda/Xeloda.htm. Accessed.